Docetaxel Plus Oxaliplatin with 5-Fluorouracil May Be Effective for Advanced Gastric Cancer

Share this content:

the Cancer Therapy Advisor take:

According to a new study published in the journal Annals of Oncology, researchers have found that the combination of docetaxel, oxaliplatin, and 5-fluorouracil (TEF) may be effective alone or as a backbone regimen for newly developed targeted agents for the treatment of patients with advanced gastric cancer.

For this phase 2 study, researchers sought to evaluate docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/capecitabine (TEX), and TEF in patients with metastatic or locally recurrent gastric adenocarcinoma. Researchers randomly assigned 248 patients with advanced gastric cancer 1:1:1 to TE, TEF, or TEX.

Results showed a median progression survival of 7.66 months (95% CI: 6.97 - 9.40) for TEF, 4.50 months (95% CI: 3.68 - 5.32) for TE, and 5.55 months (95% CI: 4.30 - 6.37) for TEX. Median overall survival was 14.59 months (95% CI: 11.70 - 21.78) for TEF, 8.97 months (95% CI: 7.79 - 10.87) for TE, and 11.30 months (95% CI: 8.08 - 14.03) for TEX.

Tumor response rate for TEF was nearly double that of TE and TEX. Adverse effects were similar across all arms. The researchers suggest that TEF should be studied in phase 3 trials for patients with advanced gastric cancer alone or with targeted therapy.

Dr. Farma provides his insight on treating the elderly patient population in the surgical oncology s
Docetaxel, oxaliplatin, and TEF may be effective for the treatment of patients with advanced gastric cancer.
This phase II study evaluated docetaxel/oxaliplatin (TE), docetaxel/oxaliplatin/5–fluorouracil (TEF) and docetaxel/oxaliplatin/capecitabine (TEX) in patients with advanced gastric cancer. The results suggest that TEF is worthy of evaluation as an arm in a phase III trial or as a backbone regimen for new targeted agents in advanced gastric cancer.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs